Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1200-1213

  Boichuk, Sergei ^a,g   Lee, Derek J ^a   Mehalek, Keith R ^a   Makielski, Kathleen R ^a   Wozniak, Agnieszka ^c   Seneviratne, Danushka S ^a   Korzeniewski, Nina ^e   Cuevas, Rolando ^a   Parry, Joshua A ^a   Brown, Matthew F ^a   Zewe, James ^a   Taguchi, Takahiro ^f   Kuan, Shin Fan ^b   Schöffski, Patrick ^c   Debiec Rychter, Maria ^d   Duensing, Anette ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MICE; MICE, NUDE; MITOXANTRONE; PLICAMYCIN; TOPOISOMERASE II INHIBITORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 84894288830     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1955     Document Type: Article

References (55)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
2. Demetri GD, Mehren von M, Blanke CD, Van den Abbeele AD, Eisen-berg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80.
3. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
4. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
5. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364: 1127-34.
6. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13.
7. Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelder-blom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
8. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:7510-8.
9. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005;6:249-51.
10. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11: 4182-90.
11. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
12. Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P, et al. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 2007;67:2685-92.
13. Bauer S, Parry JA, Muhlenberg T, Brown MF, Seneviratne D, Chatterjee P, et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res 2010;70:150-9
14. dtp.nci.nih.gov [Internet]. Available from: http://dtp.nci.nih.gov
15. Edris B, Fletcher JA, West RB, van de Rijn M, Beck AH. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma 2012;2012:805614.
16. Taguchi T, Sonobe H, Toyonaga S-I, Yamasaki I, Shuin T, Takano A, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stro-mal tumor. Lab Invest 2002;82:663-5.
17. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AGP, et al. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol 2011;5:93-104.
18. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-8.
19. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007;26: 7560-8.
20. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23: 3999-4006.
21. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009; 15:4066-76.
22. Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe J, et al. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res 2013;73:5120-9.
23. Boichuk S, Hu L, Hein J, Gjoerup OV. Multiple DNA damage signaling and repair pathways deregulated by simian virus 40 large T antigen. J Virol 2010;84:8007-20.
24. Gupta A, Roy S, Lazar AJF, Wang W-L, McAuliffe JC, Reynoso D, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA 2010; 107:14333-8.
25. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. JNCI 2011;103: 962-78.
26. Fujimoto S, Ogawa M. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol 1982;8: 157-62.
27. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 2007; 13:170-81.
28. de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-4.
29. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 1986;315:1433-8.
30. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. Cancer Res 1985;45:1879-84.
31. Ehninger G, Proksch B, Heinzel G, Woodward DL. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986;70:1373-8.
32. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993;82: 3133-40.
33. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002-9.
34. Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res 2012;72:4178-92.
35. Van Dyke MW, Dervan PB. Chromomycin, mithramycin, and olivo-mycin binding sites on heterogeneous deoxyribonucleic acid. Foot-printing with (methidiumpropyl-EDTA)iron(II). Biochemistry 1983;22: 2373-7.
36. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcrip-tional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 1991;88:1613.
37. Liu S, Wu L-C, Pang J, Santhanam R, Schwind S, Wu Y-Z, et al. Sp1/NFkB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010;17:333-47.
38. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66:9153-61.
39. Liu Y, Parry JA, Chin A, Duensing S, Duensing A. Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis. Mol Cancer 2008;7:61.
40. Mitsui A, Sharp PA. Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain. Proc Natl Acad Sci USA 1999;96:6054-9.
41. Stoimenov I, Schultz N, Gottipati P, Helleday T. Transcription inhibition by DRB potentiates recombinational repair of UV lesions in mammalian cells. PLoS ONE 2011;6:e19492.
42. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
43. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 2002;3:235-43.
44. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008;105:9053-8.
45. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37.
46. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6:645-50.
47. Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib. Cancer 2010;116:3692-701.
48. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:2693-9.
49. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 2013;12:1299-309.
50. clinicaltrials.gov [Internet]. [cited 2013 Sep 18]. Available from: http://clinicaltrials.gov.
51. Snyder RC, Ray R, Blume S, Miller DM. Mithramycin blocks transcrip-tional initiation of the c-myc P1 and P2 promoters. Biochemistry 1991;30:4290-7.
52. Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J. Inhibition of c-src transcription by ithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 2003;42: 8313-24.
53. Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 2010;8: 1271-83.
54. Ho AD, Seither E, Ma DD, Prentice HG. Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells. Br J Haematol 1987;65: 51-5.
55. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149:780-94.